220 related articles for article (PubMed ID: 25196083)
1. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Brygger L; Herrstedt J;
Expert Opin Drug Saf; 2014 Oct; 13(10):1407-22. PubMed ID: 25196083
[TBL] [Abstract][Full Text] [Related]
2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
3. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
Dogan U; Yavas G; Tekinalp M; Yavas C; Ata OY; Ozdemir K
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):462-8. PubMed ID: 22696873
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
7. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
Singh PM; Borle A; Gouda D; Makkar JK; Arora MK; Trikha A; Sinha A; Goudra B
J Clin Anesth; 2016 Nov; 34():459-82. PubMed ID: 27687434
[TBL] [Abstract][Full Text] [Related]
10. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari RM
Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Botrel TE; Clark OA; Clark L; Paladini L; Faleiros E; Pegoretti B
Support Care Cancer; 2011 Jun; 19(6):823-32. PubMed ID: 20495832
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
14. Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
Lin SJ; Hatoum HT; Buchner D; Cox D; Balu S
BMC Health Serv Res; 2012 Jul; 12():215. PubMed ID: 22823909
[TBL] [Abstract][Full Text] [Related]
15. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Mori-Vogt S; Blazer M
Expert Rev Anticancer Ther; 2013 Aug; 13(8):919-36. PubMed ID: 23984894
[TBL] [Abstract][Full Text] [Related]
16. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
17. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
18. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
19. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
Fabi A; Malaguti P
Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
[TBL] [Abstract][Full Text] [Related]
20. WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006272. PubMed ID: 24323437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]